死亡受体DR5在急性非淋巴细胞白血病细胞中的表达及其临床意义

Expression of death receptor 5 (DR5) in the cells of acute non-lymphocyte leukemia (ANLL) and its clinical significance

目的 探讨死亡受体 DR5在急性非淋巴细胞白血病(ANL L)细胞中的表达及其临床意义 .方法 培养 Jurkat,NB4细胞和抽取 ANL L患者的骨髓细胞 ,分离出单个核细胞 ,用免疫组织化学染色的方法测定 DR5的阳性表达率 ,所选病例进行诱导化疗后 ,研究 DR5的阳性表达率与诱导化疗结果的关系 .结果 DR5的阳性表达率在 Jurkat细胞中为98% ,阳性物质主要分布在胞质及胞膜中 ;而在 NB4细胞中则为 81% .不同 ANL L 患者的 DR5阳性细胞的百分率存在较大的差异 ,其中最高达 94 % ,最低为 4 5 % .ANL L患者的DR5阳性表达率与诱导化疗后骨髓涂片的原始和幼稚细胞比例呈负相关 ,与诱导化疗后的缓解率呈正相关 ;DR5的阳性表达率与 ANL L 分型无明显相关 .结论 该结果对 ANL

AIM To reveal the expression of death receptor 5 (DR5) in the cells of acute non lymphocyte leukemia (ANLL) and its clinical significance. METHODS ANLL cell line Jurkat and NB4 cells were cultured. Bone marrow cells of ANLL patients were separated. The expressions of DR5 in these cells were observed by using immunohistochemical staining method. Inducing chemotherapy was given to all cases to study the relationship between DR5 positivity rate and inducing chemotherapy results. RESULTS DR5 positivity rate was 98% in Jurkat cells with positive signals mainly located in membrane and cytoplasm, 81% in NB4 cells, and significantly different in ANLL patients, ranging from 94% to 45%. DR5 positivity rate was negatively correlated with ratio of primary cell to infantilism cell, and positively correlated with complete remission rate after inducing chemotherapy, and was not significantly correlated with ANLL clinical types. CONCLUSION The results might provide clinical significance for assessing the therapeutic effects of inducing chemotherapy for ANLL.